Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Former employees say short-staffed NC psych hospital rife with violence, abuse
Recommended
Mother's Day Deals 2024: Flowers, restaurant, retail and gift card bonus offers
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
24.48
+0.51 (+2.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
876,430
Open
24.17
Bid (Size)
23.00 (8)
Ask (Size)
26.28 (5)
Prev. Close
23.97
Today's Range
23.61 - 24.62
52wk Range
20.84 - 34.27
Shares Outstanding
115,926,629
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
May 02, 2024
Via
Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+1.32%
+1.32%
1 Month
+1.03%
+1.03%
3 Month
+11.17%
+11.17%
6 Month
-4.90%
-4.90%
1 Year
+3.03%
+3.03%
More News
Read More
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Recap: Corcept Therapeutics Q4 Earnings
February 15, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Earnings Preview: Corcept Therapeutics
February 14, 2024
Via
Benzinga
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
April 22, 2024
Via
Benzinga
Exposures
Product Safety
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
April 19, 2024
Via
Chartmill
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
April 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
March 29, 2024
Via
Chartmill
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.
March 07, 2024
Via
Chartmill
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?
February 16, 2024
Via
Benzinga
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
February 14, 2024
Via
Chartmill
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
February 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
January 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
January 24, 2024
Via
Chartmill
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
January 22, 2024
Via
Benzinga
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.